



Contents lists available at ScienceDirect

International Journal for Parasitology: Drugs and Drug Resistance

journal homepage: www.elsevier.com/locate/ijpddr

Allele specific PCR for a major marker of levamisole resistance in *Haemonchus contortus*

Alistair Antonopoulos^{a,b,*}, Stephen R. Doyle^b, David J. Bartley^c, Alison A. Morrison^c, Ray Kaplan^d, Sue Howell^e, Cedric Neveu^f, Valentina Busin^a, Eileen Devaney^g, Roz Laing^{g,**}

^a School of Veterinary Medicine, University of Glasgow, Glasgow, Scotland, United Kingdom

^b Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom

^c Moredun Research Institute, Penicuik, Scotland, United Kingdom

^d St. George's University, Grenada

^e Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, USA

^f Institut National de la Recherche Agronomique, Nouzilly, France

^g Institute of Biodiversity, Animal Health, & Comparative Medicine, University of Glasgow, Glasgow, Scotland, United Kingdom

ARTICLE INFO

Keywords:

Haemonchus
Levamisole
Resistance
Allele specific PCR
SNP
RFLP
Diagnostic
S168T

ABSTRACT

Haemonchus contortus is a haematophagous parasitic nematode that infects small ruminants and causes significant animal health concerns and economic losses within the livestock industry on a global scale. Treatment primarily depends on broad-spectrum anthelmintics, however, resistance is established or rapidly emerging against all major drug classes. Levamisole (LEV) remains an important treatment option for parasite control, as resistance to LEV is less prevalent than to members of other major classes of anthelmintics. LEV is an acetylcholine receptor (AChR) agonist that, when bound, results in paralysis of the worm. Numerous studies implicated the AChR sub-unit, ACR-8, in LEV sensitivity and in particular, the presence of a truncated *acr-8* transcript or a deletion in the *acr-8* locus in some resistant isolates. Recently, a single non-synonymous SNP in *acr-8* conferring a serine-to-threonine substitution (S168T) was identified that was strongly associated with LEV resistance. Here, we investigate the role of genetic variation at the *acr-8* locus in a controlled genetic cross between the LEV susceptible MHco3(ISE) and LEV resistant MHco18(UGA2004) isolates of *H. contortus*. Using single worm PCR assays, we found that the presence of S168T was strongly associated with LEV resistance in the parental isolates and F3 progeny of the genetic cross surviving LEV treatment. We developed and optimised an allele-specific PCR assay for the detection of S168T and validated the assay using laboratory isolates and field samples that were phenotyped for LEV resistance. In the LEV-resistant field population, a high proportion (>75%) of L₃ encoded the S168T variant, whereas the variant was absent in the susceptible isolates studied. These data further support the potential role of *acr-8* S168T in LEV resistance, with the allele-specific PCR providing an important step towards establishing a sensitive molecular diagnostic test for LEV resistance.

1. Introduction

Haemonchus contortus is one of the most pathogenic and economically important gastrointestinal nematodes (GIN) of small ruminants, and is responsible for significant welfare issues and production losses for the sheep sector worldwide (Miller et al., 2012; Emery et al., 2016; Kotze and Prichard, 2016; Besier et al., 2016; Sallé et al., 2019). Control of haemonchosis relies heavily on prophylactic and therapeutic use of broad-spectrum anthelmintics (Kotze and Prichard, 2016), however,

H. contortus shows a remarkable capacity to quickly develop resistance under drug pressure (Kaplan, 2020). Resistance to four of the major classes of anthelmintic (benzimidazoles, imidazothiazoles such as levamisole (LEV), macrocyclic lactones and amino-acetonitrile derivatives) has been reported (Sangster and Gill, 1999; Wolstenholme et al., 2004; Gilleard, 2013; Van den Brom et al., 2015) and the prevalence of multidrug resistance is increasing in many areas (Kaplan, 2004; Geurden et al., 2014; Kotze and Prichard, 2016). Resistance to LEV is less common than to other broad-spectrum anthelmintics (Cernanská

* Corresponding author. School of Veterinary Medicine, University of Glasgow, Glasgow, Scotland, United Kingdom.

** Corresponding author.

E-mail addresses: Alistair.Antonopoulos@glasgow.ac.uk (A. Antonopoulos), Rosalind.Laing@glasgow.ac.uk (R. Laing).

<https://doi.org/10.1016/j.ijpddr.2022.08.001>

Received 11 April 2022; Received in revised form 4 August 2022; Accepted 4 August 2022

Available online 10 August 2022

2211-3207/© 2022 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

et al., 2006; Van den Brom et al., 2013; Crook et al., 2016; Rose-Vineer et al., 2020) and, as such, it remains an important control option for the livestock industry.

LEV is a selective agonist of nematode acetylcholine receptors (AChRs) (Aceves et al., 1970; Martin et al., 1997; Kopp et al., 2009; Martin et al., 2012). Nematode AChRs are pentameric ligand-gated ion channels composed of five identical (homomeric) or related (heteromeric) subunits (Duguet et al., 2016). The LEV sensitive AChR in *H. contortus* is a heteropentameric complex formed from subunits UNC-38, UNC-29, UNC-63, and ACR-8 with one subunit present twice (Boulin et al., 2011; Blanchard et al., 2018). The canonical binding site for acetylcholine and the allosteric binding site for LEV are thought to be distinct but located at the interface between two receptor subunits, with ACR-8 and UNC-63 likely candidates among others (Martin et al., 2012; Duguet et al., 2016). Multiple lines of evidence, including functional reconstitution and RNAi experiments, have shown that ACR-8 plays a key role in conferring LEV sensitivity to the *H. contortus* AChR (Boulin et al., 2011; Blanchard et al., 2018).

Current understanding of LEV resistance in *H. contortus* has largely focused on three putative mechanisms: (i) the expression of truncated transcripts of *acr-8* and *unc-63* (termed *acr-8b* and *unc-63b* respectively) (Neveu et al., 2010; Fauvin et al., 2010; Boulin et al., 2011; Barrère et al., 2014), (ii) altered expression patterns of AChR subunits (including *acr-8* and *unc-63*) (Sarai et al., 2013, 2014; Raza et al., 2016), and (iii) a variable length deletion present in the second intron of the *acr-8* gene (Williamson et al., 2011; Barrère et al., 2014; dos Santos et al., 2019). The deletion in intron 2 has also been correlated with expression of *acr-8b* (Barrère et al., 2014), and it has been proposed that the two could be involved in LEV resistance (Barrère et al., 2014; dos Santos et al., 2019).

Diagnosis of anthelmintic resistance, including LEV resistance, typically relies on the faecal egg count reduction test (FECRT), which compares egg counts between pre- and post-drug anthelmintic administration (Coles et al., 1992). While faecal egg counts are relatively simple to perform and are useful for general flock management, the FECRT has significant drawbacks including poor sensitivity for detection of resistance; for the BZs, at least 25% of the population had to be resistant for detection (Martin et al., 1989). This presents serious concerns for managing the emergence of resistance, particularly for drugs where clinical efficacy remains relatively high such as LEV (Rose Vineer et al., 2020).

Molecular diagnostic tests have been demonstrated for multiple benzimidazole (BZ) resistance SNPs in parasitic nematodes using various methodologies, including allele specific (AS)-PCR, restriction fragment length polymorphism (RFLP), and pyrosequencing (Winterrowd et al., 2003; Tiwari et al., 2006; von Samson-Himmelstjerna et al., 2009; Mohanraj et al., 2017). A recent development in large scale surveillance is the ‘Nemabiome’ approach, which makes use of deep amplicon sequencing of barcoded PCR products (Avramenko et al., 2015). Although originally developed for species identification and quantification, it was recently adapted to assess the presence of BZ resistance SNPs by deep sequencing of β -tubulin amplicons (Avramenko et al., 2019; Melville et al., 2020). However, to date, no molecular diagnostic assays are described for LEV resistance surveillance.

We recently used bulk segregant analysis of a genetic cross between LEV resistant and LEV susceptible isolates of *H. contortus* together with whole-genome sequencing to identify a discrete region on Chromosome V under LEV selection (Doyle et al., 2021). This region contained gene HCON_00151270, the *H. contortus* orthologue of *C. elegans* *acr-8*. We identified a single non-synonymous SNP in *H. contortus* *acr-8* exon 4 encoding a serine-to-threonine substitution (PRJEB506: 31,521,884 bp; GCT-GGT) and refer to this variant as S168T. This was the only non-synonymous SNP identified within the exonic sequence of the *acr-8* locus in the genetic cross. This variant was highly differentiated between the susceptible and resistant parental isolates, and its frequency increased significantly in the progeny of the genetic cross after LEV

selection. Notably, the serine residue at this position was highly conserved amongst parasitic Clade V nematodes, yet a serine-to-threonine substitution was also found at the corresponding position of the *acr-8* orthologue in LEV resistant *Teladorsagia circumcincta* (Choi et al., 2017; Doyle et al., 2021). Here we build upon these population-level findings to validate the S168T variant using single worm genotyping of *H. contortus* L₃ from both parental isolates and the genetic cross pre- and post-LEV treatment, and describe the development of an optimised allele-specific PCR (AS-PCR) to detect LEV resistant and susceptible *acr-8* alleles in laboratory and field populations.

2. Materials and methods

2.1. Animal handling and ethics statement

All experimental procedures were examined and approved by the Animal Welfare Ethical Review Board of the Moredun Research Institute, Penicuik, Scotland and were conducted under approved UK Home Office licenses following the Animals (Scientific Procedures) Act of 1986. The Home Office licence number is PPL 60/03899.

2.2. *H. contortus* isolates

The *H. contortus* samples used in this study were from the LEV susceptible MHco3(ISE) (Otsen et al., 2001; Roos et al., 2004) isolate, the LEV resistant MHco18(UGA2004) (Williamson et al., 2011) isolate, and the progeny of a genetic cross between these isolates termed MHco3/18, originally described in Doyle et al. (2018). In addition, two LEV susceptible geographically divergent isolates: MHco4(WRS) (van Wyk et al., 1987) and MHco10(CAVR) (Le Jambre et al., 1995) were also used. All isolates were maintained and passed through parasite-naïve sheep at the Moredun Research Institute. In brief, the MHco3/18 line was established by crossing immature MHco3(ISE) females with immature MHco18(UGA2004) males at 14 days post infection. Infective larvae from the MHco3/18 cross were used to infect parasite naïve lambs to generate two further filial generations, followed by *in vivo* selection of the F2 generation by treatment of three infected animals with 7.5 mg/kg body weight levamisole hydrochloride (Levacide, Low Volume, Norbrook Laboratories Ltd) (Doyle et al., 2021). Eggs from the F3 generation were collected from donor sheep pre-treatment and again at 21 days post-treatment, after which they were cultured to L₃ (Coop et al., 1982). All populations of L₃ were either maintained at 8 °C in tap water or cryopreserved in liquid nitrogen. Adult worms collected from sheep at post-mortem were sexed then cryopreserved in liquid nitrogen.

Field samples were collected in the Southern USA and phenotyped using a commercial larval development assay (DrenchRite®). For LEV, resistant populations have an EC₅₀ \geq 1.56 μ M and susceptible populations have an EC₅₀ \leq 0.78 μ M. Farm 001 was highly LEV resistant (EC₅₀: 9.36 μ M) and Farm 002 was LEV susceptible (EC₅₀: 0.57 μ M). Farm 001 corresponds to Farm 7 in Doyle et al. (2021), Farm 002 corresponds to Farm 4 in Doyle et al. (2021).

2.3. DNA extraction

Pooled gDNA was extracted from frozen aliquots of \sim 10,000 L₃ by a modified phenol chloroform extraction. Briefly, 20 μ l (20 mg/ μ l) Proteinase K (Invitrogen, 25530015) and 300 μ l lysis buffer (200 mM NaCl, 100 mM Tris-HCl, 30 mM EDTA, 0.5% SDS) was added to a pellet of worms, incubated at 55 °C for 2 h, after which 10 μ l (10 mg/ml) RNase A was added and incubated at 37 °C for 10 min. Phenol/chloroform/isomyl alcohol (25:24:1; 550 μ l) was then added, shaken, and incubated at R/T for 5 min, then centrifuged at 14000 \times g for 15 min at R/T. The top layer was removed to a fresh tube and 200 μ l chloroform was added, and the resultant mixture centrifuged at 14000 \times g for 15 min at R/T. The top layer was again removed to a fresh tube and combined with 0.1 volume of 3 M sodium acetate, three volumes of 100% ethanol, and 2 μ l

glycogen, followed by overnight incubation at -80°C . The following day, the mixture was centrifuged at $14000\times g$ at 4°C for 45 min, the supernatant aspirated and $500\ \mu\text{l}$ 70% ethanol added before centrifuging at $14000\times g$ at 4°C for 5 min. Finally, the pellet was air dried, and resuspended in $10\ \mu\text{l}$ elution buffer (Qiagen, 19086). The DNA concentration was calculated using a Qubit Spectrophotometer (Qubit dsDNA HS kit; Invitrogen, Q33231) and diluted to $100\ \text{ng}/\mu\text{l}$.

Crude lysates of single worms were produced as follows: $10\ \mu\text{l}$ lysis buffer (100X stock solution: $1000\ \mu\text{l}$ Direct PCR Lysis Reagent (Cell) (Viagen, 301-C), $50\ \mu\text{l}$ 1 M DTT (Invitrogen, P2325), and $10\ \mu\text{l}$ Proteinase K (100 mg/ml) (Invitrogen, 25530049)) was aliquoted per well of a 96 well PCR plate. One L_3 was picked into each well in a volume of $<1\ \mu\text{l}$ of water. Lysates were incubated at 60°C for 2 h, followed by 85°C for 45 min to denature the Proteinase K.

2.4. Primer design and amplicon sequencing

Illumina reads from whole-genome sequencing of pools of 200 MHco3(ISE), MHco18(UGA2004), and MHco3/18 L_3 (Doyle et al., 2021) were mapped to the PRJEB506 MHco3(ISE).4.0 assembly (Doyle et al., 2019). Reads aligning to the *acr-8* genomic locus (HCON_00151270, 2020-04-PRJEB506. WBPS13 Wormbase annotation) were visualised in Geneious (Biomatters Ltd: 11.1.5) to identify between-isolate polymorphisms. Consensus sequences were generated for each isolate to simplify primer design. However, population-level data was also examined to ensure that there were no moderate frequency mutations that could disrupt primer binding sites. Generic and AS-PCR primers (Table 1) were manually designed in Geneious and supplied by Eurofins Genomics, Ebersberg, Germany. Deletion spanning primers (Hco-indel-F and Hco-indel-R) were designed ~ 50 bp up and downstream of the deletion locus, to allow sufficient size difference between amplicons for discrimination of PCR products via gel electrophoresis (Fig. 1A). Indel specific primer Hco-Indel-Ins-R was designed within the region of the deletion locus that was conserved in the 97 bp deletion described by Doyle et al. (2021) and the 63 bp deletion described by Barrère et al. (2014) (Fig. 1B). This was done to account for potential variation between isolates in the size and locus of the deletion in individual L_3 based on previous reports (Barrère et al., 2014).

AS-PCR primers were designed with mismatches introduced at the 2nd and 5th bases from the 3' end, for both the susceptible and resistant primers, in addition to a SNP-specific mismatch (PRJEB506 position: 31,521,884 bp) at the most 3' base for the resistant primers only (Fig. 1C). For two genetically divergent laboratory isolates ((MHco4 (WRS) and MHco10(CAVR)), published whole genome sequencing reads (Redman et al., 2012; Gilleard, 2013) were mapped to the genome and the *acr-8* genomic locus was visualised as described above. Two synonymous SNPs, C-T (PRJEB506 position: 31,521,901) and A-G (PRJEB506 position: 31,521,895), were identified in a high proportion

of reads from both MHco4(WRS) and MHco10(CAVR). As both SNPs lie within the primer binding site for the allele-specific primers, deoxyinosine bases were substituted at position 17 from the 5' end of the Hco-168T-R and Hco-168S-R primers, respectively. These primers are termed Hco-168T [I]-R/Hco-168S [I]-R.

2.5. Reaction-specific conditions for PCRs and RFLP

2.5.1. Size discrimination PCR for *acr-8* intron 2 deletion

The intron 2 region was amplified from genomic DNA with GoTaq G2 Flexi DNA polymerase (Promega, M7801) in a final volume of $20\ \mu\text{l}$ as follows: $1\ \mu\text{l}$ of crude lysate was added to $5\ \mu\text{l}$ 5X Green GoTaq Flexi Buffer, $8\ \mu\text{l}$ 25 mM MgCl_2 , $1\ \mu\text{l}$ 10 mM dNTP mix (Promega, U1511), $1\ \mu\text{l}$ F and R primer ($100\ \text{pmol}$), $0.25\ \mu\text{l}$ GoTaq G2 Flexi DNA polymerase, $3.75\ \mu\text{l}$ DNase/RNase-free water and amplified as follows: initial denaturation 95°C for 2 min, followed by 35 cycles (denaturation 95°C for 30 s, primer annealing temperature (T_A) $^{\circ}\text{C}$ for 30 s, and extension 72°C for 15 s with a final extension at 72°C for 5 min) using primers Hco-Indel-F and R, or Hco-Indel-F and Hco-Indel-Ins-R. All PCR products were visualised on 2% agarose gel with SafeView Nucleic Acid Stain. Identity of PCR products was confirmed by capillary sequencing (Eurofins, Ebersberg, Germany).

2.5.2. Two-step nested PCR and RFLP for S168T

The first round of the two-step nested PCR protocol for RFLP amplified the exon 4 region (PRJEB506 position: 31,521,758–31,522,025 bp) from single worm lysates as described in 2.5.1 except using primers Hco-Intron4-F and Hco-Exon4-R. A $1\ \mu\text{l}$ aliquot of the PCR product from round 1 was diluted 1:20 and added to $19\ \mu\text{l}$ GoTaq G2 Flexi PCR reaction mix using primers Hco-Exon4-F and Hco-Exon4-R and amplified as follows: initial denaturation 95°C for 2 min, followed by 40 cycles (denaturation 95°C for 30 s, annealing T_A $^{\circ}\text{C}$ for 30 s, and extension 72°C for 15 s) with the final extension at 72°C for 5 min. $20\ \mu\text{l}$ of nested PCR product was digested using *Ava*II (NEB, R0153S) for 7–12 h at 37°C in CutSmart buffer (NEB, B7204S). Digested products were then visualised on a 4% NuSieve (Lonza, 50090) agarose gel with SafeView Nucleic Acid Stain.

2.5.3. Optimisation of AS-PCR for S168T with cloned fragments

Cloned *acr-8* exon 4 fragments for both S168T variants (GCT from MHco3(ISE), GGT from MHco18(UGA2004)) were used to optimise the AS-PCR; these provided abundant template and removed the complexity of additional polymorphisms at the primer binding sites in individual worms during early optimisation. Target sequences for *acr-8* exon 4 were amplified from MHco3(ISE) and MHco18(UGA2004) single worm lysates (2.3; 2.5.4), using Phusion HiFi PCR (Hco-Intron4-F/Hco-Exon4-R) and cloned using TOPO™ TA Cloning™ with One Shot™ TOP10 chemically competent *E. coli* cells (Invitrogen, K450001) or XL10-Gold

Table 1

Table of primer sequences used in this study.

Primer Name	Target	Sequence (5'–3') ^{a,b}	Annealing Temperature (T_A)	Reference
Hco-Indel-F	<i>acr-8</i> intron 2 deletion	ATTCTTGCCGTTATTACACC	56°C	Current study
Hco-Indel-R	<i>acr-8</i> intron 2 deletion	GGAGGGAGCTTCAGCTTTT	56°C	Current study
Hco-Indel-Ins-R	<i>acr-8</i> intron 2 deletion	GCGATATAACAGCAGTTAAC	56°C	Current study
Hco-Exon4-F	<i>acr-8</i> exon 4	AGATAGGAGAAGTGGCCG	55°C	Current study
Hco-Intron4-F	<i>acr-8</i> exon 4	TGTATTTCGTGCAGAGATAGG	55°C	Current study
Hco-Exon4-R	<i>acr-8</i> exon 4	AATTATGAGCGATGCCCTC	55°C	Current study
Hco-168T-R	S168T GGT	TTAAATTTGGAGGAaGGtc	60°C	Current study
Hco-168S-R	168S GCT	TTAAATTTGGAGGAaGGtg	60°C	Current study
Hco-168T [I]-R	S168T GGT	TT [I]AAATTTGGAGGAaGGtc	60°C	Current study
Hco-168S [I]-R	168S GCT	TT [I]AAATTTGGAGGAaGGtg	60°C	Current study
Hco-ITS2-F	<i>H. contortus</i> ITS2	GTTACAATTTTCATAACATCACGT	50°C	Redman et al. (2008)
Hco-ITS2-R	<i>H. contortus</i> ITS2	TTTACAGTTTGCAAGACTTA	50°C	Redman et al. (2008)

F denotes forward primer, R denotes reverse.

^a For allele-specific primers, mismatches relative to the sequence are denoted by lower case.

^b Deoxyinosine base modification is denoted by [I].




Fig. 1. Schematic representation of primer design. A: Indel spanning primers (Table 1: Hco-Indel-R and Hco-Indel-F). If the deletion is present, then the product size will differ from the full-length allele, allowing for a size discrimination PCR to determine the genotype of the individual. B: Deletion specific primer (Table 1: Hco-Indel-Ins-R). The deletion specific primer lies wholly within the deleted sequence, thus blocking amplification if the deletion is present. C: Schematic representation of allele-specific primer function. The allele-specific primer binds upstream of the discriminating allele in both sensitive and resistant DNA, however, the ability of the primer to facilitate DNA extension during PCR depends specifically on the nucleotide at the 3' end of the primer. Additional nucleotide mismatches at the 2nd and 5th position from the 3' end of the primer (indicated by red X) are identical in each set and enhance the destabilisation of the polymerisation complex in the case of an allele specific mismatch at the 3' position to discriminate between the two alleles: GGT (168T/resistant) and GCT (168S/susceptible). The 3' mismatch is allele specific, and as shown by the example above will prevent polymerisation and amplification if the S168T variant is present. In the resistant primer assay, the opposite occurs. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

ultracompetent *E. coli* cells (Agilent, 200315) according to the manufacturer's instructions. Colonies were cultured on LB-Agar with 100 µg/ml ampicillin (Sigma Aldrich, A9518) and screened using X-gal (Promega, V3941) blue/white colony screening. White colonies were picked and further screened with RFLP (section 2.5.2) to identify the presence of GGT or GCT exon 4 fragments. Colonies containing the required insert/allele were sub-cultured on LB-Agar with 100 µg/ml ampicillin. Plasmid isolation was carried out using QIAprep Spin mini-prep kit (Qiagen, 27104) according to manufacturer instructions. Liquid cultures were grown up overnight in 5 ml of LB broth with 100 µg/ml ampicillin. Purified plasmid was capillary sequenced by Eurofins Genomics, Ebersberg, Germany according to company instructions.

Primer candidates Hco-168T-R and Hco-168S-R were predicted to discriminate between GCT and GGT *in silico* based on WGS for both isolates and sequencing of the clones. Gradient PCR using plasmid as template was used initially to establish the optimal T_A of each primer candidate and the optimal forward primer pairing. Best results were obtained by pairing Hco-Exon4-F/Hco-168T-R (132 bp amplicon) or Hco-Intron4-F/Hco-168S-R (148 bp amplicon). Touchdown-PCR cycles were then added to improve specificity and eliminate non-specific amplification. Extensive experimentation was carried out to optimise PCR conditions including polymerase, temperature, touchdown cycle number and duration, optimal dilution of first round PCR product, and dNTP and primer concentration.

2.5.4. AS-PCR for S168T with single worm lysates

First-round PCR amplification of exon 4 was carried out on 1 µl of single worm lysate using Phusion Green High-Fidelity DNA Polymerase (Thermo Scientific, F534S) in a final volume of 20 µl as follows: 4 µl 5X HF reaction buffer, 0.2 µl 10 mM dNTP mix, 0.1 µl Hco-Intron4-F/Hco-Exon4-R primers (100 pmol), 0.2 µl Phusion DNA Polymerase, 14.5 µl DNase/RNase-free water. The PCR programme was as follows: initial denaturation for 30 s at 98 °C, followed by 35 cycles (denaturation 98 °C for 10 s, annealing T_A °C for 10 s, and extension 72 °C for 10 s) with the final extension 72 °C for 5 min.

A second-round PCR amplification with allele-specific primers was carried out using DreamTaq DNA Polymerase (Thermo Scientific, EP0702) PCR in a final volume of 20 µl as follows: 2 µl 10X reaction buffer, 0.05 µl 10 mM dNTP mix, 0.025 µl Hco-Exon4-F/Hco-168T-R or Hco-Intron4-F/Hco-168S-R (100 pmol), 0.2 µl DreamTaq polymerase,

16.9 µl DNase/RNase-free water, and 1 µl of the first-round PCR product diluted 1:10–1:20. The PCR programme using a touchdown PCR was as follows: initial denaturation for 2 min at 95 °C, followed by 12 touchdown PCR cycles (denaturation 95 °C for 30 s, annealing first temperature 68 °C for 30 s, annealing last temperature 60 °C (decreasing in equal increments per cycle) for 30 s, and extension 72 °C for 15 s), followed by ten PCR cycles (denaturation 95 °C for 30 s, annealing temperature 60 °C for 30 s, and extension 72 °C for 15 s) with the final extension of 72 °C for 5 min. PCR products were visualised on a 2% agarose gel stained with SYBR Safe DNA Gel Stain (Thermo Fisher, S33102).

2.5.5. ITS2 *H. contortus* species identification PCR

ITS2 species identification PCR was carried out on 1 µl of single worm lysate using Phusion Green High-Fidelity DNA Polymerase (Thermo Scientific, F534S) in a final volume of 20 µl as described in 2.5.4 except using Hco-ITS2-F/Hco-ITS2-R (Redman et al., 2008). The PCR programme was as follows: initial denaturation for 30 s at 98 °C, followed by 35 cycles (denaturation 98 °C for 10 s, annealing T_A °C for 10 s, and extension 72 °C for 10 s) with the final extension 72 °C for 5 min.

3. Results

3.1. Detection of the *acr-8* intron 2 deletion in LEV resistant and susceptible *H. contortus* L₃

A previous study suggested an association between an indel in intron 2 of *acr-8* and LEV resistance in *H. contortus* (Barrère et al., 2014). Alignment of WGS to the reference genome showed a 97 bp deletion in the MHco18(UGA2004) and MHco3/18 isolates which increased in frequency from 73.47% to 86.58% in WGS data from MHco3/18 F3 progeny following LEV selection of the F2 parental generation (Doyle et al., 2021). Primers were designed to bind ~50 bp upstream and downstream of this region and used to investigate its utility as a genetic marker of LEV resistance by size discrimination PCR. Genotyping of individual L₃ from the MHco18(UGA2004) and MHco3(ISE) isolates demonstrated that the deletion was present in a high proportion of both populations (Fig. 2A and B; Supplementary Table 1). Of 135 MHco3(ISE) worms genotyped, 64% (n = 87) were found to be homozygous for the




Fig. 2. Summary of *acr-8* intron 2 deletion in MHco18(UGA2004) and MHco3(ISE) L₃. Size discrimination PCR (Fig. 1A) was developed to genotype individual L₃ based on the presence or absence of the deletion allele. A deletion specific confirmation PCR (Fig. 1B) was then developed to validate the results of the size discrimination PCR. A: Example gel of single worm PCR of MHco18(UGA2004) and MHco3(ISE) with indel spanning (~50 bp up and downstream of deletion locus) primer set (Hco-Indel-F/Hco-Indel-R). Odd numbers: MHco18(UGA2004). Even numbers: MHco3(ISE). The 245 bp band corresponds to full length allele, the 149 bp band corresponds to deletion allele. B: Bar chart showing proportion of deletion (D) allele detected by RFLP in LEV resistant MHco18(UGA2004), LEV susceptible MHco3(ISE), and MHco3/18 genetic cross populations. Y axis: genotype frequency. Genotypes DD: homozygous deletion; DF: heterozygous; FF: homozygous full length. C: Single worm PCR with indel internal (will only anneal when deleted sequence is present) confirmation (Hco-Indel-F/Hco-Indel-Ins-R) primer set: 1,3,5 MHco18(UGA2004); 2,4 MHco3(ISE) single L₃ worms; 6 Positive Control (100 ng) pooled L₃ MHco3(ISE) gDNA. D: Single worm PCR with indel spanning (Hco-Indel-F/Hco-Indel-R) primer set: 1,3,5 MHco18(UGA2004), 2,4; MHco3(ISE) single L₃, 6 NTC. The same individual L₃ lysate was used for PCR shown in C and D.

deletion compared with 92% (n = 44) of the 48 MHco18(UGA2004). A confirmatory PCR with a primer designed to span the deletion locus (i.e., can only anneal if the deletion is absent) (Fig. 2C) was performed. A full concordance (100%, n = 5) was found between the indel and confirmatory PCR (Fig. 2C and D). Overall, these data show that the intron 2 deletion is present at a relatively high frequency in the MHco3(ISE) isolate of *H. contortus* (Fig. 2B; Supplementary Fig. 1).

3.2. Detection of S168T (GCT/GGT) in LEV resistant *H. contortus* L₃

Having identified a high frequency of individuals with the *acr-8* indel in a fully LEV susceptible population, we focused our efforts on validating variant S168T in individual worms. Initially, we developed an RFLP assay, which could discriminate between the two alleles based on the introduction of an *Ava*II restriction site by the variant. This initial assay was useful for identifying GCT (encoding serine = susceptible/S) homozygotes and individuals with at least one GGT (encoding threonine

= resistant/R) allele, and we were able to show that the S168T allele was present in a high proportion of MHco18(UGA2004) and MHco3/18, and absent in MHco3(ISE) (Fig. 3A). However, it was not always possible to differentiate GGT homozygotes and heterozygotes, due to incomplete digestion (Fig. 3B). For this reason, we focused our efforts on the development of an AS-PCR assay to discriminate between the two alleles (Fig. 4).

Allele-specific primers were designed to discriminate between GCT and GGT alleles and PCR conditions were optimised as described in Methods (2.5.4, 2.5.5). These primers were initially used to genotype individual L₃ from MHco18(UGA2004) and MHco3(ISE) populations. Of the MHco3(ISE) L₃ assayed, 100% were homozygous for GCT (SS) (n = 32) (Fig. 5A), while ~96% of MHco3(UGA2004) (n = 71) showed at least one GGT (R) allele, of which ~31% were homozygous GGT (RR) and ~65% were heterozygous (RS), with ~4% homozygous GCT (SS) (Fig. 5B).

We then genotyped F3 larvae of the MHco3/18 cross collected pre-




Fig. 3. Summary of RFLP analysis of MHco18(UGA2004), MHco3(ISE) and MHco3/18 L₃. S168T (GCT-GGT) mutation at codon 168 introduces an *Ava*II restriction site. Restriction Fragment Length Polymorphism (RFLP) was developed to genotype individual MHco3(ISE), MHco18(UGA2004), and MHco3/18 L₃ for the presence of either the GCT (susceptible - S) or the GGT (resistant - R) allele. A: Bar chart showing proportion of GGT allele detected by RFLP in LEV resistant MHco18(UGA2004), LEV susceptible MHco3(ISE), and MHco3/18. Y axis: genotype frequency. B: Detection of GGT by single L₃ *Ava*II RFLP in LEV resistant MHco18(UGA2004), LEV susceptible MHco3(ISE), and MHco3/18 genetic cross. 1: MHco18(UGA2004); 2: MHco3(ISE); 3: MHco3/18. 237 bp bands represents 168S GCT sequence. 128 bp and 109 bp bands represent GGT sequence. Predicted genotypes RR: homozygous GGT; RS: heterozygous; SS: homozygous GCT.




Fig. 4. Flow diagram summarising design, establishment, and validation of the AS-PCR for the detection of the S168T variant in multiple *H. contortus* isolates: the LEV susceptible MHco3(ISE), MHco4(WRS), and MHco10(CAVR), and the LEV resistant MHco18(UGA2004) and MHco3/18, and one phenotypically LEV resistant, and one phenotypically LEV susceptible field isolate from the USA.




Fig. 5. 16 LEV resistant MHco18(UGA2004) and 16 LEV susceptible MHco3(ISE) L₃ were analysed on 2% agarose gel: A: MHco3(ISE): 1: Hco-Exon4-F + Hco-168T-R. 2: Hco-Intron4-F + Hco-168S-R. B: MHco18(UGA2004): 1: Hco-Exon4-F + Hco-168T-R. 2: Hco-Intron4-F + Hco-168S-R. Predicted genotypes RR: homozygous GGT; RS: heterozygous; SS: homozygous GCT. “-” indicates this individual did not amplify by PCR. Only wells that amplified by PCR are counted in the final percentages (Fig. 6; Supplementary Table 3).

and post-LEV administration. A moderate proportion of GGT alleles were expected in the pre-treatment samples as this population is an admixture of MHco18(UGA2004) and MHco3(ISE) alleles and the RFLP assay previously showed a high proportion of individuals in the untreated population encoded at least one GGT allele (Fig. 3; Supplementary Table 2). With AS-PCR, pre-LEV administration, ~58% MHco3/18 individuals showed at least one GGT (R) allele, of which ~9% were RR and 48% were RS, with ~42% SS (n = 85). Post-LEV administration, the proportion of individuals with a resistance allele increased: ~75% of MHco3/18 individuals showed at least one GGT (R) allele, of which ~16% were RR and ~58% were RS, with ~25% SS (n = 79) (Fig. 6; Supplementary Tables 3 and 4). The pre-treatment population was in Hardy-Weinberg equilibrium (HWE) ($\chi^2 = 0.81$, p = 0.29),

whereas post treatment the population was not in HWE ($\chi^2 = 3.26$, p = 0.043), with an excess of heterozygotes.

Finally, the AS-PCR was used to genotype *H. contortus* field populations from two farms in the USA. DrenchRite® larval development assays predicted Farm 001 to be LEV resistant (EC₅₀: 9.36 μ M) and Farm 002 to be LEV susceptible (EC₅₀: 0.57 μ M). 80% of L₃ from Farm 001 showed at least one GGT (R) allele, of which 32% were RR and 48% were RS, with 20% SS (n = 59). In contrast, 100% of individuals from Farm 002 were SS (n = 38) (Fig. 6; Supplementary Table 3). Farm 002, however, also showed a high percentage of amplification failure (only 59% of 64 wells amplified).

A control PCR targeting a conserved multi-copy locus (ITS2) (Redman et al., 2008) was carried out on the 64 individuals from Farm 002 to




Fig. 6. Bar chart showing the proportion of GGT allele detected by AS-PCR in LEV resistant MHco18(UGA2004), LEV susceptible MHco3(ISE), and pre and post single LEV administration MHco3/18, LEV resistant (Farm 001) and LEV susceptible (Farm 002) field populations from the USA. Genotypes RR: homozygous GGT; RS: heterozygous; SS: homozygous GCT.

determine if the PCR failure in many wells was due to the sample quality of the starting material or polymorphism at the *acr-8* primer binding sites. Following *H. contortus* ITS2 PCR, there was a strong correlation between the band intensity of the two independent PCRs (Supplementary Fig. 2). This suggested that the sample quality and/or the concentration of the sample was impacting both PCRs in the same way, indicating degradation of sample material was the most likely explanation, and not genetic variation differentially impacting the two populations.

3.3. Deoxyinosine modification of primers optimises S168T GGT allele detection in divergent LEV susceptible isolates

Following optimisation of the AS-PCR in MHco3(ISE) and MHco18 (UGA2004) populations, it was tested on two geographically separated LEV susceptible laboratory isolates MHco4(WRS) (van Wyk et al., 1987)

and MHco10(CAVR) (Le Jambre et al., 1995). These isolates were originally derived from field populations in South Africa and Australia, respectively. The S168T variant (GGT) is not present in pooled WGS sequencing data available for these isolates (Doyle et al., 2019). Initial experiments using the standard AS-PCR primers and conditions (2.5.4) showed no amplification at the previously optimal dilution of 1:20 used for the first-round PCR. The dilution factor was then decreased to 1:8, and although this led to improvements in amplification, it also led to non-specific annealing of the resistant primer (Fig. 7A and B). However, using the deoxyinosine substituted primers Hco-168T [I]-R and Hco-168S [I]-R resulted in a marked improvement in both the specificity and sensitivity of the amplification in MHco4(WRS) and MHco10 (CAVR) (Fig. 7C and D). The deoxyinosine primer showed all individuals assayed to be homozygous for the S168 allele.




Fig. 7. Comparison gel showing difference between unmodified (Hco-168T-R/Hco-168S-R) and deoxyinosine modified (Hco-168T [I]-R/Hco-168S [I]-R) primers on geographically divergent LEV susceptible isolates MHco4(WRS) and MHco10(CAVR): Hco-168T-R/Hco-168S-R primers (panels A and B) 1:8 diluted first round exon 4 PCR products from MHco4 (WRS) and MHco10(CAVR). Hco-168T [I]-R/Hco-168S [I]-R primers (C and D) 1:20 diluted first-round exon 4 PCR products from MHco4(WRS) and MHco10 (CAVR). Lanes 1–8: individual L₃ worms. The same eight individual L₃ from each isolate were used to compare primer sets.

3.4. Discussion

In this study, we sought to characterise putative genetic mechanisms of LEV resistance, with the aim of developing a proof-of-concept diagnostic test that could be used to genotype LEV resistant and susceptible *H. contortus* populations. Proof-of-concept diagnostic assays are considered an essential step towards improving resistance management and surveillance (Kotze et al., 2020), particularly in the face of growing multi-drug resistance (Rose Vineer et al., 2020). Given the current limitations of the available tests to diagnose LEV resistance in *H. contortus*, we sought to directly address this need by developing an allele-specific PCR.

We undertook extensive single worm genotyping to investigate the presence of the intron 2 deletion. Data from WGS showed that the deletion allele was present within untreated L₃ of the MHco3/18 genetic cross and increased in frequency following LEV treatment, but this analysis was based on sequencing of pooled L₃ (Doyle et al., 2021). In the current study, we demonstrated using single worm genotyping that the indel was present and homozygous at a high frequency in both susceptible and resistant isolates. Previous studies have suggested that the high proportion of deletion alleles seen in susceptible populations is due to heterozygous individuals, and thus qPCR could be used as a quantitation-based prediction of resistance in a population (dos Santos et al., 2019). However, this was not supported by our results; given that the majority of individuals in a LEV susceptible population are homozygous for the deletion, it is unlikely to serve as an effective diagnostic marker of LEV resistance. Our results are more consistent with a recent study using droplet digital PCR comparing the presence of the intron 2 deletion in Swedish field-derived and laboratory populations of *H. contortus*; although there was a difference in genotype frequencies between resistant and susceptible isolates, the homozygous deletion was present in a high proportion of susceptible isolates (Baltrusis et al., 2021).

We then sought to characterise the S168T variant, the only non-synonymous SNP in *acr-8* in the MHco18(UGA2004) isolate relative to the fully susceptible MHco3(ISE) isolate (Doyle et al., 2021). Fortunately, the S168T (GCT/GGT) variant produced an allele specific restriction site that could be differentiated by an RFLP assay (Fig. 3). However, while the RFLP was found to accurately predict the presence of the GGT allele, it was at times difficult to determine if an individual was RR or RS due to the presence and varying intensity of the upper (uncut) fragment. In addition, the requirement for overnight digestion with a restriction enzyme makes the RFLP sub-optimal for a large-scale study or eventual deployment to a diagnostic laboratory.

To overcome these issues, we designed an AS-PCR for quicker and more accurate genotyping of *H. contortus* individuals. The AS-PCR offers marked improvement compared to RFLP, and can deliver a faster, cheaper, and more accurate assay. AS-PCR eliminated the issue of ambiguous heterozygotes and provides a time to result of under 3 h (6 h including crude lysate production). The AS-PCR was sensitive and specific on single L₃, and we were able to demonstrate a high frequency of the S168T variant in LEV resistant laboratory and field populations, and its absence in LEV susceptible laboratory and field populations. As a proof-of-concept diagnostic assay, the AS-PCR provides the potential for significant improvement on current diagnostic practices for LEV resistance based on the FECRT or other *in vitro* assays (Kotze et al., 2020). In addition, as our assay uses a two-step nested PCR, the *acr-8* exon 4 template generated by the first round PCR could also be integrated into the Nemabiome deep amplicon sequencing system (Avramenko et al., 2019; Melville et al., 2020). This has the added benefit of allowing for increased multifunctionality and improved resistance surveillance for LEV on a larger scale.

Previous work on *H. contortus* suggests that, in some isolates, LEV resistance can be considered a recessive trait (Dobson et al., 1996; Sangster et al., 1998). If LEV resistance is recessive and conferred by the S168T variant alone, we would expect all surviving adults should be RR

and all progeny should be RR with no survival of RS or SS genotypes. However, although we observed a significant increase in RR individuals after treatment, we also identified a large proportion of RS individuals in addition to a small proportion of SS larvae. To investigate this observation further we genotyped a small number of F₂ adults (n = 10) surviving LEV treatment at the S168T locus and found the presence of two SS individuals (data not shown). The presence of fully susceptible adults following LEV treatment suggests either S168T is a linked marker, rather than a mutation conferring resistance, or there are additional resistance mechanisms beyond *acr-8* S168T alone (Neveu et al., 2010; Fauvin et al., 2010; Boulin et al., 2011). Given the conservation of serine at codon 168 across different nematode species and the presence of S168T in LEV resistant *T. circumcincta* (Choi et al., 2017; Doyle et al., 2021), we believe it is likely that S168T is involved in the mechanism of resistance. The presence of a threonine residue at the homologous position in *C. elegans* *acr-8*, T171, is also significant. In the *C. elegans* *lev-8* null mutant AChR, LEV-8 is replaced by ACR-8, with this receptor showing lower sensitivity to LEV (Qian et al., 2008; Hernando et al., 2012). Preliminary *in silico* protein modelling of *H. contortus* ACR-8 revealed that residue 168 lies in the extracellular β -loop domain, which forms part of the theorised orthosteric binding site for LEV (Martin et al., 2012). Although the serine-threonine substitution does not represent a significant change in the overall properties of the amino acid, and is unlikely to destabilise the tertiary structure due to alterations in charge or solubility, it may be a sufficient conformational change to inhibit efficient binding of LEV. It is not currently known if the S168T variant alters transcript expression in *H. contortus*.

Furthermore, we have recently identified a second QTL in the MHco3/18 cross following LEV selection containing HCON_00107690 (*lev-1.1*) and HCON_00107700 (*lev-1.2*) on Chromosome IV (Doyle et al., 2021), which is suggestive of additional mechanisms of resistance. *Lev-1* has previously been implicated in LEV resistance in *C. elegans* (Fleming et al., 1997; Qian et al., 2008). However, its role in LEV resistance in *H. contortus* remains unclear, as it is thought to lack a signal peptide for membrane insertion, and experiments in *Xenopus* oocytes showed that *H. contortus* LEV-1 was not required for a functional reconstituted receptor (Boulin et al., 2011). Further work is required to understand the relative contribution of mutations in *acr-8* and at the *lev-1* locus, as well as in other commonly implicated loci, in the LEV resistance phenotype.

A limitation of a PCR-based diagnostic is the potential for genetic variation in the primer binding sites to interfere with the primer binding and therefore assay efficiency. This is a legitimate concern, given that populations of *H. contortus* are known to be highly genetically diverse throughout the world (Yin et al., 2013; Sallé et al., 2019). To investigate the possibility of developing an assay for S168T in divergent populations, the AS-PCR was tested on two LEV susceptible isolates, MHco4 (WRS) and MHco10(CAVR), from South Africa and Australia respectively. We initially found that the AS-PCR performed poorly on these isolates and, confirmed via ITS2 species identification PCR, that this was likely due to sequence differences rather than availability of starting template. As simply decreasing the dilution factor in these isolates led to non-specific amplification, deoxyinosine [I] bases were introduced in the primers to accommodate two synonymous SNPs that were identified at the primer bind site. [I] base pairing allows for “universal” pairing at base positions likely to exhibit polymorphism, albeit with a preferential order for pairing (I-C > I-A > I-G/I-T) (Case-Green and Southern, 1994). This follows an approach used to develop a universal (i.e. detecting all four serotypes) Dengue Virus PCR primer set (Wang et al., 2000), a pathogen that also displays very high levels of sequence polymorphism. The introduction of a single [I] base (Hco-168T [I]-R/Hco-168S [I]-R) at the site of the most frequent SNP led to a marked increase in both specificity and sensitivity of the assay, restoring amplification at 1:20 dilution. The consistency of the amplification was also markedly improved. The introduction of a second [I] base (Hco-168T [II]-R/Hco-168S [II]-R) however, compromised the primer binding under the current reaction conditions at all dilutions tested (data not

shown). Thus, further optimisation will be necessary to overcome the issues of non-specific amplification and produce a truly global *H. contortus* LEV resistance assay primer set. Alternatively, it may be necessary to develop region specific primer sets for optimal diagnostic performance, an undertaking that would be facilitated by the global diversity database of *H. contortus* (Sallé et al., 2019).

4. Conclusion

In conclusion, we investigated two mutations at the *acr-8* locus proposed to be associated with LEV-resistance in *H. contortus*. Of these, only the SNP marker S168T consistently discriminated between susceptible and resistant L₃ of all populations tested by single worm genotyping. While it is likely that LEV resistance is multigenic, our data further implicates S168T as a major diagnostic marker. We developed an optimised AS-PCR for the detection of this SNP in *H. contortus* and show that the modification of a primer set with an [I] base presents a potential solution to dealing with genetically divergent populations. This proof-of-concept molecular assay provides the starting point for a sensitive diagnostic test for LEV resistance in global populations of *H. contortus*.

Declaration of competing interest

The authors report that they have no conflict of interest.

Acknowledgements

This work was funded by a James Herriot Scholarship (Glasgow University Vet Fund) and a Biotechnology and Biological Sciences Research Council (BBSRC) strategic Lola [BB/M003949]. SRD is supported by a UKRI Future Leaders Fellowship [MR/T020733/1] and RL is supported by a Wellcome Clinical Research Career Development Fellowship [216614/Z/19/Z]. DB and AM are supported by the Scottish Government's Rural and Environment Science and Analytical Services (RESAS) division. This research was funded in whole, or in part, by the Wellcome Trust. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijpddr.2022.08.001>.

References

Aceves, J., Eerlij, D., Martínez-Marañón, R., 1970. The mechanism of the paralyzing action of tetramisole on *Ascaris* somatic muscle. *Br. J. Pharmacol.* 38, 602–607.

Avramenko, R.W., Redman, E.M., Lewis, R., Yazwinski, T.A., Wasmuth, J.D., Gilleard, J.S., 2015. Exploring the gastrointestinal "Nemabiome": deep amplicon sequencing to quantify the species composition of parasitic nematode communities. *PLoS One* 10, e0143559.

Avramenko, R.W., Redman, E.M., Melville, L., Bartley, Y., Wit, J., Queiroz, C., Bartley, D. J., Gilleard, J.S., 2019. Deep amplicon sequencing as a powerful new tool to screen for sequence polymorphisms associated with anthelmintic resistance in parasitic nematode populations. *Int. J. Parasitol.* 49, 13–26.

Baltrušis, P., Charvet, C.L., Halvarsson, P., Mikko, S., Höglund, J., 2021. Using droplet digital PCR for the detection of hco-*acr-8b* levamisole resistance marker in *H. contortus*. *Int J Parasitol Drugs Drug Resist* 15, 168–176.

Barrère, V., Beech, R.N., Charvet, C.L., Prichard, R.K., 2014. Novel assay for the detection and monitoring of levamisole resistance in *Haemonchus contortus*. *Int. J. Parasitol.* 44, 235–241.

Besier, R.B., Kahn, L.P., Sargison, N.D., Van Wyk, J.A., 2016. Diagnosis, treatment and management of *Haemonchus contortus* in small ruminants. *Adv. Parasitol.* 93, 181–238.

Blanchard, A., Guegnard, F., Charvet, C.L., Crisford, A., Courtot, E., Sauve, C., Harmache, A., Duguet, T., O'Connor, V., Castagnone-Sereno, P., Reaves, B., Wolstenholme, A.J., Beech, R.N., Holden-Dye, L., Neveu, C., 2018. Deciphering the molecular determinants of cholinergic anthelmintic sensitivity in nematodes: when novel functional validation approaches highlight major differences between the model *Caenorhabditis elegans* and parasitic species. *PLoS Pathog.* 14, e1006996.

Boulin, T., Fauvin, A., Charvet, C.L., Cortet, J., Cabaret, J., Bessereau, J.L., Neveu, C., 2011. Functional reconstitution of *Haemonchus contortus* acetylcholine receptors in *Xenopus* oocytes provides mechanistic insights into levamisole resistance. *Br. J. Pharmacol.* 164, 1421–1432.

Case-Green, S.C., Southern, E.M., 1994. Studies on the base pairing properties of deoxynosine by solid phase hybridisation to oligonucleotides. *Nucleic Acids Res.* 22, 131–136.

Cernanská, D., Várady, M., Corba, J., 2006. A survey on anthelmintic resistance in nematode parasites of sheep in the Slovak Republic. *Vet. Parasitol.* 135, 39–45.

Choi, Y.-J., Bisset, S.A., Doyle, S.R., Hallsworth-Pepin, K., Martin, J., Grant, W.N., Mitreva, M., 2017. Genomic introgression mapping of field-derived multiple-anthelmintic resistance in *Teladorsagia circumcincta*. *PLoS Genet.* 13, e1006857.

Coles, G.C., Bauer, C., Borgsteede, F.H., Geerts, S., Klei, T.R., Taylor, M.A., Waller, P.J., 1992. World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) methods for the detection of anthelmintic resistance in nematodes of veterinary importance. *Vet. Parasitol.* 44, 35–44.

Coop, R.L., Sykes, A.R., Angus, K.W., 1982. The effect of three levels of intake of *Ostertagia circumcincta* larvae on growth rate, food intake and body composition of growing lambs. *J. Agric. Sci.* 98, 247–255.

Crook, E.K., O'Brien, D.J., Howell, S.B., Storey, B.E., Whitley, N.C., Burke, J.M., Kaplan, R.M., 2016. Prevalence of anthelmintic resistance on sheep and goat farms in the mid-Atlantic region and comparison of *in vivo* and *in vitro* detection methods. *Small Rumin. Res.* 143, 89–96.

Dobson, R.J., LeJambre, L., Gill, J.H., 1996. Management of anthelmintic resistance: inheritance of resistance and selection with persistent drugs. *Int. J. Parasitol.* 26, 993–1000.

dos Santos, J., Vasconcelos, J.F., Frota, G.A., Freitas, E.P., Teixeira, M., Vieira, L.D.S., Bevilacqua, C.M.L., Monteiro, J.P., 2019. Quantitative molecular diagnosis of levamisole resistance in populations of *Haemonchus contortus*. *Exp. Parasitol.* 205, 107734.

Doyle, S.R., Illingworth, C.J.R., Laing, R., Bartley, D.J., Redman, E., Martinelli, A., Holroyd, N., Morrison, A.A., Rezansoff, A., Tracey, A., Devaney, E., Berriman, M., Sargison, N., Cotton, J.A., Gilleard, J.S., 2019. Population genomic and evolutionary modelling analyses reveal a single major QTL for ivermectin drug resistance in the pathogenic nematode, *Haemonchus contortus*. *BMC Genom.* 20, 218.

Doyle, S.R., Laing, R., Bartley, D., Morrison, A., Holroyd, N., Maitland, K., Antonopoulos, A., Chaudhry, U., Flis, I., Howell, S., McIntyre, J., Gilleard, J.S., Tait, A., Mable, B., Kaplan, R., Sargison, N., Britton, C., Berriman, M., Devaney, E., Cotton, J.A., 2021. 2021. Genomic landscape of drug response reveals novel mediators of anthelmintic resistance. *bioRxiv* 2011 (2012), 465712.

Doyle, S.R., Laing, R., Bartley, D.J., Britton, C., Chaudhry, U., Gilleard, J.S., Holroyd, N., Mable, B.K., Maitland, K., Morrison, A.A., Tait, A., Tracey, A., Berriman, M., Devaney, E., Cotton, J.A., Sargison, N.D., 2018. A genome resequencing-based genetic map reveals the recombination landscape of an outbred parasitic nematode in the presence of polyploidy and polyandry. *Genome Biol Evol* 10, 396–409.

Doyle, S.R., Tracey, A., Laing, R., Holroyd, N., Bartley, D., Bazant, W., Beasley, H., Beech, R., Britton, C., Brooks, K., Chaudhry, U., Maitland, K., Martinelli, A., Noonan, J.D., Paulini, M., Quail, M.A., Redman, E., Rodgers, F.H., Sallé, G., Shabbir, M.Z., Sankaranarayanan, G., Wit, J., Howe, K.L., Sargison, N., Devaney, E., Berriman, M., Gilleard, J.S., Cotton, J.A., 2020. Genomic and transcriptomic variation defines the chromosome-scale assembly of *Haemonchus contortus*, a model gastrointestinal worm. *Commun Biol* 3, 656.

Duguet, T.B., Charvet, C.L., Forrester, S.G., Wever, C.M., Dent, J.A., Neveu, C., Beech, R. N., 2016. Recent duplication and functional divergence in parasitic nematode levamisole-sensitive acetylcholine receptors. *PLoS Neglected Trop. Dis.* 10, e0004826.

Emery, D.L., Hunt, P.W., Le Jambre, L.F., 2016. *Haemonchus contortus*: the then and now, and where to from here? *Int. J. Parasitol.* 46, 755–769.

Fauvin, A., Charvet, C., Issouf, M., Cortet, J., Cabaret, J., Neveu, C., 2010. cDNA-AFLP analysis in levamisole-resistant *Haemonchus contortus* reveals alternative splicing in a nicotinic acetylcholine receptor subunit. *Mol. Biochem. Parasitol.* 170, 105–107.

Fleming, J.T., Squire, M.D., Barnes, T.M., Tornøe, C., Matsuda, K., Ahn, J., Fire, A., Sulston, J.E., Barnard, E.A., Sattelle, D.B., Lewis, J.A., 1997. *Caenorhabditis elegans* levamisole resistance genes *lev-1*, *unc-29*, and *unc-38* encode functional nicotinic acetylcholine receptor subunits. *J. Neurosci.* 17, 5843–5857.

Geurden, T., Hoste, H., Jacquiet, P., Traversa, D., Sotiraki, S., Frangipane di Regalbono, A., Tzanidakis, N., Kostopoulou, D., Gaillac, C., Privat, S., Giangaspero, A., Zanardello, C., Noe, L., Vanimisetti, B., Bartram, D., 2014. Anthelmintic resistance and multidrug resistance in sheep gastro-intestinal nematodes in France, Greece and Italy. *Vet. Parasitol.* 201, 59–66.

Gilleard, J.S., 2013. *Haemonchus contortus* as a paradigm and model to study anthelmintic drug resistance. *Parasitology* 140, 1506–1522.

Hernando, G., Bergé, I., Rayes, D., Bouzat, C., 2012. Contribution of subunits to *Caenorhabditis elegans* levamisole-sensitive nicotinic receptor function. *Mol. Pharmacol.* 82, 550–560.

Kaplan, R.M., 2004. Drug resistance in nematodes of veterinary importance: a status report. *Trends Parasitol.* 20, 477–481.

Kaplan, R.M., 2020. Biology, epidemiology, diagnosis, and management of anthelmintic resistance in gastrointestinal nematodes of livestock. *Vet Clin North Am Food Anim Pract* 36, 17–30.

Kopp, S.R., Coleman, G.T., Traub, R.J., McCarthy, J.S., Kotze, A.C., 2009. Acetylcholine receptor subunit genes from *Ancylostoma caninum*: altered transcription patterns associated with pyrantel resistance. *Int. J. Parasitol.* 39, 435–441.

Kotze, A.C., Gilleard, J.S., Doyle, S.R., Prichard, R.K., 2020. Challenges and opportunities for the adoption of molecular diagnostics for anthelmintic resistance. *Int J Parasitol Drugs Drug Resist* 14, 264–273.

- Kotze, A.C., Prichard, R.K., 2016. Anthelmintic resistance in *Haemonchus contortus*: history, mechanisms and diagnosis. *Adv. Parasitol.* 93, 397–428.
- Le Jambre, L.F., Gill, J.H., Lenane, I.J., Lacey, E., 1995. Characterisation of an avermectin resistant strain of Australian *Haemonchus contortus*. *Int. J. Parasitol.* 25, 691–698.
- Martin, P.J., Anderson, N., Jarrett, R.G., 1989. Detecting benzimidazole resistance with faecal egg count reduction tests and *in vitro* assays. *Aust. Vet. J.* 66, 236–240.
- Martin, R.J., Robertson, A.P., Bjorn, H., 1997. Target sites of anthelmintics. *Parasitology* 114 (Suppl. 1), S111–S124.
- Martin, R.J., Robertson, A.P., Buxton, S.K., Beech, R.N., Charvet, C.L., Neveu, C., 2012. Levamisole receptors: a second awakening. *Trends Parasitol.* 28, 289–296.
- Melville, L.A., Redman, E., Morrison, A.A., Rebecca Chen, P.C., Avramenko, R., Mitchell, S., Van Dijk, J., Innocent, G., Sargison, F., Aitken, C., Gilleard, J.S., Bartley, D.J., 2020. Large scale screening for benzimidazole resistance mutations in *Nematodirus battus*, using both pyrosequencing and deep amplicon sequencing, indicates the early emergence of resistance on UK sheep farms. *Int J Parasitol Drugs Drug Resist* 12, 68–76.
- Miller, C.M., Waghorn, T.S., Leathwick, D.M., Candy, P.M., Oliver, A.M., Watson, T.G., 2012. The production cost of anthelmintic resistance in lambs. *Vet. Parasitol.* 186, 376–381.
- Mohanraj, K., Subhadra, S., Kalyanasundaram, A., Ilangopathy, M., Raman, M., 2017. Genotyping of benzimidazole resistant and susceptible isolates of *Haemonchus contortus* from sheep by allele specific PCR. *J. Parasit. Dis.* 41, 282–288.
- Neveu, C., Charvet, C.L., Fauvin, A., Cortet, J., Beech, R.N., Cabaret, J., 2010. Genetic diversity of levamisole receptor subunits in parasitic nematode species and abbreviated transcripts associated with resistance. *Pharmacogenetics Genom.* 20, 414–425.
- Otsen, M., Hoekstra, R., Plas, M.E., Buntjer, J.B., Lenstra, J.A., Roos, M.H., 2001. Amplified fragment length polymorphism analysis of genetic diversity of *Haemonchus contortus* during selection for drug resistance. *Int. J. Parasitol.* 31, 1138–1143.
- Qian, H., Robertson, A.P., Powell-Coffman, J.A., Martin, R.J., 2008. Levamisole resistance resolved at the single-channel level in *Caenorhabditis elegans*. *Faseb. J.* 22, 3247–3254.
- Raza, A., Kopp, S.R., Bagnall, N.H., Jabbar, A., Kotze, A.C., 2016. Effects of *in vitro* exposure to ivermectin and levamisole on the expression patterns of ABC transporters in *Haemonchus contortus* larvae. *Int J Parasitol Drugs Drug Resist* 6, 103–115.
- Redman, E., Packard, E., Grillo, V., Smith, J., Jackson, F., Gilleard, J.S., 2008. Microsatellite analysis reveals marked genetic differentiation between *Haemonchus contortus* laboratory isolates and provides a rapid system of genetic fingerprinting. *Int. J. Parasitol.* 38, 111–122.
- Redman, E., Sargison, N., Whitelaw, F., Jackson, F., Morrison, A., Bartley, D.J., Gilleard, J.S., 2012. Introgression of ivermectin resistance genes into a susceptible *Haemonchus contortus* strain by multiple backcrossing. *PLoS Pathog.* 8, e1002534.
- Roos, M.H., Otsen, M., Hoekstra, R., Veenstra, J.G., Lenstra, J.A., 2004. Genetic analysis of inbreeding of two strains of the parasitic nematode *Haemonchus contortus*. *Int. J. Parasitol.* 34, 109–115.
- Rose Vineer, H., Morgan, E.R., Hertzberg, H., Bartley, D.J., Bosco, A., Charlier, J., Chartier, C., Claerebout, E., de Waal, T., Hendrickx, G., Hinney, B., Höglund, J., Ježek, J., Kašný, M., Keane, O.M., Martínez-Valladares, M., Mateus, T.L., McIntyre, J., Mickiewicz, M., Munoz, A.M., Phythian, C.J., Ploeger, H.W., Rataj, A., V., Skuce, P.J., Simin, S., Sotiraki, S., Spinu, M., Stuen, S., Thamsborg, S.M., Vadlejch, J., Varady, M., von Samson-Himmelstjerna, G., Rinaldi, L., 2020. Increasing importance of anthelmintic resistance in European livestock: creation and meta-analysis of an open database. *Parasite* 27, 69.
- Sallé, G., Doyle, S.R., Cortet, J., Cabaret, J., Berriman, M., Holroyd, N., Cotton, J.A., 2019. The global diversity of *Haemonchus contortus* is shaped by human intervention and climate. *Nat. Commun.* 10, 4811.
- Sangster, N.C., Gill, J., 1999. Pharmacology of anthelmintic resistance. *Parasitol. Today* 15, 141–146.
- Sangster, N.C., Redwin, J.M., Bjorn, H., 1998. Inheritance of levamisole and benzimidazole resistance in an isolate of *Haemonchus contortus*. *Int. J. Parasitol.* 28, 503–510.
- Sarai, R.S., Kopp, S.R., Coleman, G.T., Kotze, A.C., 2013. Acetylcholine receptor subunit and P-glycoprotein transcription patterns in levamisole-susceptible and -resistant *Haemonchus contortus*. *Int J Parasitol Drugs Drug Resist* 3, 51–58.
- Sarai, R.S., Kopp, S.R., Coleman, G.T., Kotze, A.C., 2014. Drug-efflux and target-site gene expression patterns in *Haemonchus contortus* larvae able to survive increasing concentrations of levamisole *in vitro*. *Int J Parasitol Drugs Drug Resist* 4, 77–84.
- Tiwari, J., Kumar, S., Kolte, A.P., Swarnkar, C.P., Singh, D., Pathak, K.M., 2006. Detection of benzimidazole resistance in *Haemonchus contortus* using RFLP-PCR technique. *Vet. Parasitol.* 138, 301–307.
- Van den Brom, R., Moll, L., Borgsteede, F.H., Van Doorn, D.C., Lievaart-Peterson, K., Dercksen, D.P., Vellema, P., 2013. Multiple anthelmintic resistance of *Haemonchus contortus*, including a case of moxidectin resistance, in a Dutch sheep flock. *Vet. Rec.* 173, 552.
- Van den Brom, R., Moll, L., Kappert, C., Vellema, P., 2015. *Haemonchus contortus* resistance to monepantel in sheep. *Vet. Parasitol.* 209, 278–280.
- van Wyk, J.A., Malan, F.S., Gerber, H.M., Alves, R.M., 1987. Two field strains of *Haemonchus contortus* resistant to radoxanide. *Onderstepoort J. Vet. Res.* 54, 143–146.
- von Samson-Himmelstjerna, G., Walsh, T.K., Donnan, A.A., Carrière, S., Jackson, F., Skuce, P.J., Rohn, K., Wolstenholme, A.J., 2009. Molecular detection of benzimidazole resistance in *Haemonchus contortus* using real-time PCR and pyrosequencing. *Parasitology* 136, 349–358.
- Wang, W.K., Lee, C.N., Kao, C.L., Lin, Y.L., King, C.C., 2000. Quantitative competitive reverse transcription-PCR for quantification of dengue virus RNA. *J. Clin. Microbiol.* 38, 3306–3310.
- Williamson, S.M., Storey, B., Howell, S., Harper, K.M., Kaplan, R.M., Wolstenholme, A.J., 2011. Candidate anthelmintic resistance-associated gene expression and sequence polymorphisms in a triple-resistant field isolate of *Haemonchus contortus*. *Mol. Biochem. Parasitol.* 180, 99–105.
- Winterrowd, C.A., Pomroy, W.E., Sangster, N.C., Johnson, S.S., Geary, T.G., 2003. Benzimidazole-resistant beta-tubulin alleles in a population of parasitic nematodes (*Cooperia oncophora*) of cattle. *Vet. Parasitol.* 117, 161–172.
- Wolstenholme, A.J., Fairweather, I., Prichard, R., von Samson-Himmelstjerna, G., Sangster, N.C., 2004. Drug resistance in veterinary helminths. *Trends Parasitol.* 20, 469–476.
- Yin, F., Gasser, R.B., Li, F., Bao, M., Huang, W., Zou, F., Zhao, G., Wang, C., Yang, X., Zhou, Y., Zhao, J., Fang, R., Hu, M., 2013. Genetic variability within and among *Haemonchus contortus* isolates from goats and sheep in China. *Parasites Vectors* 6, 279.